Drug Profile
Research programme: oncology and inflammatory therapies - Eli Lilly and Company/Hutchison China MediTech
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; Hutchison MediPharma
- Developer Hutchison MediPharma
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Hong Kong
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Hong Kong
- 20 Aug 2007 Preclinical trials in Cancer in Hong Kong (unspecified route)